CN106668008A - Target anti-cancer medicine based on STAT3 (Signal Transducers and Activators of Transcription type 3) protein target spot - Google Patents
Target anti-cancer medicine based on STAT3 (Signal Transducers and Activators of Transcription type 3) protein target spot Download PDFInfo
- Publication number
- CN106668008A CN106668008A CN201510757621.9A CN201510757621A CN106668008A CN 106668008 A CN106668008 A CN 106668008A CN 201510757621 A CN201510757621 A CN 201510757621A CN 106668008 A CN106668008 A CN 106668008A
- Authority
- CN
- China
- Prior art keywords
- stat3
- cell
- compound
- cancer
- stat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 title abstract description 18
- 102000004169 proteins and genes Human genes 0.000 title abstract description 16
- 238000013518 transcription Methods 0.000 title abstract description 5
- 230000035897 transcription Effects 0.000 title abstract description 5
- 239000012190 activator Substances 0.000 title abstract description 4
- 230000001093 anti-cancer Effects 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 229940126701 oral medication Drugs 0.000 claims description 2
- 239000013002 intravenous (IV) drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000033228 biological regulation Effects 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 230000003834 intracellular effect Effects 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 101150099493 STAT3 gene Proteins 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 41
- 238000006366 phosphorylation reaction Methods 0.000 description 32
- 230000026731 phosphorylation Effects 0.000 description 30
- 230000003993 interaction Effects 0.000 description 17
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 15
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 15
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 230000019491 signal transduction Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 13
- 238000003032 molecular docking Methods 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000003119 immunoblot Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000001994 activation Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000004088 simulation Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 230000006266 hibernation Effects 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000002457 bidirectional effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 102000005869 Activating Transcription Factors Human genes 0.000 description 2
- 108010005254 Activating Transcription Factors Proteins 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000013439 planning Methods 0.000 description 2
- FHMDYDAXYDRBGZ-UHFFFAOYSA-N platinum tin Chemical compound [Sn].[Pt] FHMDYDAXYDRBGZ-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- -1 sulphonyl Amine Chemical class 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- PTCAIPUXGKZZBJ-UHFFFAOYSA-N 11-deoxocucurbitacin I Natural products CC12CCC3(C)C(C(C)(O)C(=O)C=CC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PTCAIPUXGKZZBJ-UHFFFAOYSA-N 0.000 description 1
- CCTJHVLTAJTPBV-UHFFFAOYSA-N 2-chloro-1,4-naphthoquinone Chemical class C1=CC=C2C(=O)C(Cl)=CC(=O)C2=C1 CCTJHVLTAJTPBV-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 101150113776 LMP1 gene Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000004617 QSAR study Methods 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 101710103851 Tyrosine-protein kinase transforming protein Abl Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000276425 Xiphophorus maculatus Species 0.000 description 1
- 102000009899 alpha Karyopherins Human genes 0.000 description 1
- 108010077099 alpha Karyopherins Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- NISPVUDLMHQFRQ-ILFSFOJUSA-N cucurbitacin I Natural products CC(C)(O)C=CC(=O)[C@](C)(O)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC=C4[C@@H](C=C(O)C(=O)C4(C)C)[C@]3(C)C(=O)C[C@]12C NISPVUDLMHQFRQ-ILFSFOJUSA-N 0.000 description 1
- NISPVUDLMHQFRQ-MKIKIEMVSA-N cucurbitacin I Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)/C=C/C(C)(O)C)C=C2[C@H]1C=C(O)C(=O)C2(C)C NISPVUDLMHQFRQ-MKIKIEMVSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000013209 evaluation strategy Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920001469 poly(aryloxy)thionylphosphazene Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- ZRRGOUHITGRLBA-UHFFFAOYSA-N stattic Chemical compound [O-][N+](=O)C1=CC=C2C=CS(=O)(=O)C2=C1 ZRRGOUHITGRLBA-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a target anti-cancer medicine based on an STAT3 (Signal Transducers and Activators of Transcription type 3) protein target spot. Cell lines of a plurality of types of breast cancers have an abnormal regulation and control mechanism of an intracellular STAT3 signal conduction system. The invention provides one type of compound, which is an effective regulator of STAT3 signal conduction, and can be applied to preparation of medicines for treating breast cancer.
Description
Technical field
The present invention relates to a kind of application of signal transducting system inhibitor compound in terms for the treatment of cancer medicine is prepared.
Background technology
Cancer becomes the Chinese national health of impact and causes one of factor of heavy economic losses.Traditional treatment cancer
The control of method-operation, radiotherapy, chemotherapy and biological therapy to the tumour patient state of an illness has certain limitation.Calendar year 2001, the first generation
The appearance of targeted drug-Gleevec brings new favourable turn and hope to the clinical treatment of cancer patient, and aobvious with clinical efficacy
The advantages of writing less with toxic and side effect.Target medicine-the Conmana of the treatment nasopharyngeal carcinoma of Chinese unique independent research is attacked
Biology target spot be EGF-R ELISA (EGFR), this with treatment non-small cell lung cancer Gefitinib target spot thunder
Together, the innovation of shortage target spot, indication are single, totally reflect the more American-European backwardness of R & D Level of the original medicine of domestic targeting.Plus
It, the patient's drug resistance and import targeted drug that the targeted drug for having come out causes in clinical Long-Time Service is expensive so that visiting
The new biological targets of cancer and research and development novel targets targeted drug is asked to become the task of top priority.Signal Transducer and
Activator of Transcription type3 are (referred to as:STAT3) it is a kind of signal transduction and activating transcription factor, its
Albumen receives much concern at present as the novel targets of therapy-related cancer, STAT3 and head and neck cancer, breast cancer, lung cancer, prostate cancer and
The generation of many cancers such as leukaemia, shift and go back to the nest closely related.The STAT3 inhibitor of international correlative study report also has:
STAT 21 (biologically active of the compound of two generations optimization is not improved), STATTIC (interact without compound-protein
Structural model, structure optimization is had no way of handling) and Hong Kong Chinese University research report suppression nasopharyngeal carcinoma cucurbitacin I (naturalization
Compound modification is more difficult).In a word, the target spot now for the targeting antitumor medicine of clinical treatment tends to Cell signal propagation pathways
Upstream, easily cause drug resistance, and be based on STAT3 target spots can effectively overcome this weakness grinding medicine.This project is adopted
With the drug design theory and efficient drug screening flow process of international advanced protein molecular target, from nearly 1,000,000 compounds
First generation compound is filtered out in the compound library of structure, according to 27 higher compound groups of biologically active compound is established
Quantitative structure activity relationship model, the biologically active of the lead compound after optimization significantly improves compared with the first generation, is international STAT3 suppressions
The latest developments in preparation research field.Project application people find third generation STAT3 inhibitor living body biological activity rating compared with
More than the high twice of taxol, meet the pharmacokinetics standard and internal medication standard of oral drugs.This project relies on Henan big
Huaihe River hospital is learned, using the organic synthesis ability and medicine vivo assessment system of pharmaceutical college in natural drug and immune engineering laboratory
System, and by means of U.S. side up to the advanced preparation process of medical science Co., Ltd, medicine generation, Safety Assessment System and abundant medicine
Thing managerial experiences etc., must produce a desired effect, and realize the key breakthrough of long-term program for the development of science and technology in country.
We intend to solve the Drug-resistant sex chromosome mosaicism occurred in clinical cancer targeted therapy.Introducing the advanced medicine of American side
While appraisement system and preparation process, with its efficient medicine management regulation and the Chinese independent knowledge of clinical method for transformation exploitation are ground
The targeting type new drug of property right, and build combination medicine research and development centre of Sino-U.S..The research and development of this project will successfully facilitate China's cancer to control
The important breakthrough for the treatment of method, promotes Chinese Medical Industry's to be converted from imitated sexual norm to innovative pattern, accelerates long-term in country
The realization of goal of science and technology development planning.Simultaneously we push away advanced drug screening and drug evaluation strategy with Chinese characteristics
Guang Dao worlds pharmaceutical field, international sale is applied to the cancer clinical treatment in the U.S., brings up Chinese single variety target medicinal and exists
Leading situation in international pharmaceutical industries like product, while declaring clinical trial and the production batch of Chinese CFDA and U.S. FDA
Number, seek medicament research and development and declare the new international cooperation pattern of " two-orbit parallel propulsion ".The STAT3 of this Project-developing suppresses
Agent breaches at present limitation of the targeting cancer therapy based on the target spot of the signal transduction such as EGFR, ABL upstream both at home and abroad, belongs to sulphonyl
Amine, synthesizes with low cost, it is contemplated that price is only the 1/3 of the price of Conmana, and the 1/20 of Gleevec, research and develop and be successfully expected into
The just novel targets targeting type new drug of Chinese first independent research, its feature be evident in efficacy, anticancer spectrum it is wider, cheap and
The features such as replacement cycle is shorter, researches and develops and will successfully lift the R & D Level of the original target medicinal of Chinese Medical Industry's, drives
Chinese Medical Industry's are converted from imitated property Industry Model to innovation mode.This project meets《Long-term Science and Technology is sent out in country
Exhibition planning outline (2006-2020)》The preferential problem of major fields ":The preventing and treating of tumour and great NCD.
STAT families and physiological mechanism Signal transducer and activator of transcription are simple
Referred to as Stat, is signal transduction and activating transcription factor.Stat families include STAT1,2,3,4,5a, 5b and 6, are one group endogenous
The cell transcription factor of property.Janus Kinase are referred to as Jak, including Jak1, and 2,3 and Tyk2, it is one group and ceases manner of breathing with Stats
The non-receptor tyrosine kinase of pass.The organic cooperations of Jak-Stat build the cellular signal transduction of one group of important mammal
Approach, and many important cytokine signalings can be transmitted in core from cells in vitro, so as to control the transcription of target gene
With the expression of downstream protein.Multinomial related Research Literature report:It is normal thin that Jak-Stat signal transduction paths participate in regulation
The breeding of born of the same parents, differentiation and apoptosis.Seven Stats protein of all mammals all have six structural regions:The first petiolareas of N
(ND), composite screw area (CC), DNA lands (DBD), bonding pad (LD), Src homeodomains 2 (SH2), C termination environments turn
Record activation domain (CD).Cell factor (Cytokine) triggers the Dimerized (dimerization) or many of acceptor with receptor binding
Multimerizing (oligomerization) and allow Jaks phosphorylations (phosphorylation) to activate Jak-Stat signals, lead to
Cross in recipient cell after birth the phosphorylation of the specific tyrosine of C termination environments many places and combined with the SH2 regions of Stat, so as to complete to receive
The combination of body-Stat.The activation of Stat interacts the N sections of unphosphorylated hibernation state Stat the antiparallel dimerization to be formed
Body Conformation transition is the parallel conformation of the bidirectional crossed interaction in the SH2 regions of activated state Stat of phosphorylation.Activation
Stat3 dimers are transferred in nucleus by the assistance of related input carrier (importin-alpha), and with it is specific
DNA target mark is combined (see figure one).Stat causes Chromosome recombination with other transcription factor interactions.Nucleoprotein tyrosine phosphorus
Acidifying (N-PTPs) is assisted Stat to depart from DNA and Stat non-phosphorylatings is converted to hibernation state so as to the activated state for completing Stat,
And it is finally completed the circulation of Stat hibernation state-activated state-hibernation state.Cytokine signaling albumen inhibiting factor (SOCS2) is formed
Negative regulator is circulated, and cuts off the conduction of Jak-Stat signals.Activation Stat albumen inhibiting factors (PIAS) by blocking dna and
The combination of Stat3 is suppressing the activity (1) of Stat.
The relation of Stat3 and Stat1 and cancer is in cell proliferation and breaks up, IL-s of the Stat3 in inhibited apoptosis
Play a crucial role in 6-gp130 signal transduction paths, for example, (IL-6)-gp130-Stat3 signal transductions participate in regulation and control B cell
Differentiation is shaped as the thick liquid cell of antibody.Stat3 participates in the signal transduction path of various IL-6 families, including IL-6, leukaemia suppression
The factor (LIF) processed, ciliary nerve nutrition is because of (CNTF), tumour inhibitor-M (OSM), the myocardial nutrition factor 1 (CT1).Stat3 is various
The downstream regulatory factor of kinases.Such as:V-abl, LMP1, v-eyk, HTLV-1, c-src and Jak family.Jak-Stat3 Non-intermittents
It is excited cause many cancers, such as:Head and neck neoplasm (> 90%), breast cancer, acute myelogenous leukemia (AML) is chronic
Lymphatic leukemia (CLL).Stat1 is uniquely to participate in the signal transduction of interferon gamma to suppress the Stat families of cell proliferation
Member, although Stat1 can be activated together with Stat3 sometimes, but mainly Cell growth inhibition, Stat1 is considered as tumour suppression
The factor processed.The tumour growth for rejecting the mouse of the carrying malignant tumour of Stat1 genes is swifter and more violent (2) than the development of wild type.
Stat3 SH2 regions are converted into activated state by hibernation state and are joined as the theoretical foundation Stat albumen of pharmacological target
In the signal transduction of relevant cell factor, including two important steps:One is special by terminal many places in own cells film
The tyrosine for determining phosphorylation completes the process that acceptor recruits Stat with Stat SH2 regional interactions;Second, passing through Stat
The specific phosphorylation of C-terminal tyrosine (pTyr705) and the SH2 regions of corresponding Stat bidirectional crossed interaction, Stat-
Stat forms the activated state dimer of parallel conformation.Block in the mechanism of pTyr-SH2 areas interaction using Stat3,5
Stat3,5 activity, to realize suppressing abnormal Stat3,5 signals to conduct in cancer cell, is a cancer cell specific induction of apoptosis and controls
The more fabulous conceptual frame (1-4) of cancer.
Stat SH2 regions are the protein modules that a class possesses about 100 amino acid.The function in SH2 regions is specificity
Identification phosphorylation tyrosine and position it.In Jak-Stat signal transduction paths, tyrosine phosphorylation cause albumen-
Interaction between albumen, and activate with forming waterfall type.Receive with endochylema based intracellular cvtokine including Stat SH2 regions
The tyrosine of SH2 regions and specific phosphorylation in the interaction of the tyrosine of the C- ends phosphorylation of body and dimer
(pTyr705) intersect interact (3,4).
The main secondary structure in SH2 areas includes:Big β-the platy structure of two alpha-helixs and one.Cytokine receptor born of the same parents
Stat3 C- ends phosphorylation in the feature that combined of peptide sequence pYXXQ and Stat3 SH2 region and activated state dimer of slurry C-terminal
The features that combined with Stat3 SH2 regions of TYR peptide sequence PpYLKTK show Stat3 SH2 and other molecule phases jointly
The characteristics of interaction.Positioned at the N- ends in β-platy structure central authorities, Arg β B5 (R609/Stat3, R618/Stat5) is and phosphorylation
The key position that tyrosine is combined, two oxygen molecules of phosphorylated tyrosine side chain form pole with the side chain of Arg β B5 basic amine groups
Property adds the interaction of electrostatic.The amino acid of the C-terminal of phosphotyrosine peptide and Stat SH2 mono- deep hydrophobic region (its
Have W623/Stat3, W641/Stat5 including important characteristic amino acid) interact.So, the computer that we select is matched somebody with somebody
The field of force region of position simulation (docking) mainly includes phosphorylated tyrosine action site Arg β B5 (R609/Stat3, R618/
Stat5) and hydrophobic effect site (W623/Stat3, W641/Stat5) (3,4).
The content of the invention
The invention mainly solves the technical problem of controlling in preparation there is provided a kind of signal transducting system inhibitor compound
Treat the application in terms of cancer drug.
For achieving the above object, the invention provides the compound of general formula is preparing treating cancer medicine or controlling
Treat the application in psoriasis drug object space face:
Molecular docking test result indicate that Cpd0460 can with Stat3 Protein Ss H2 interval (domain) crucial amino
Acid-lysine K591 and arginine R609, and hydrophobic cave that SH2 is interval (mainly by valine V637, glutamine Q635, color
Propylhomoserin W632, tyrosine Y640 and tyrosine Y657 constitute) produce strong interaction, so as to block polypeptide in phosphorylated tyrosine
With the interaction in the interval, cause to block the Stat3 albumen attached collection and Stat3 protein activations on cytokine receptor pair
The formation of body conformation, and then reach the effect for suppressing Stat3 signal transductions and cancer cell specific induction of apoptosis (see Fig. 2).BIAcore's
Experimental evidence proves that Cpd0460 can form strong interaction (see figure in low concentration (in striving unexpectedly with MALDI-PSD) and Stat3
3).The experimental evidence of protein immunoblot (Westernblot) proves that Cpd0460 can effectively suppress at low concentrations Stat3
Phosphorylation and downstream signal transduction (see Fig. 4).MTT cell apoptosis assays evidence proves that Cpd0460 can be lured at low concentrations
Lead the Apoptosis (see Fig. 5) of a series of breast cancer cancer cell strong to Stat3 signal transduction dependences.
Description of the drawings
Fig. 1 is Stat3 signal transducting system schematic diagrames;Cell factor (Cytokine) triggers the two of acceptor with receptor binding
Multimerizing (dimerization) or polymer (oligomerization), and make Jaks phosphorylations
(phosphorylation) so as to activate Jak-Stat signals, by the phosphorus of the specific tyrosine of C termination environments in recipient cell after birth
Acidifying makes that Stat is attached to be combined on acceptor;After phosphoric acid, Stat forms the binary parallel conformation of bidirectional crossed interaction;It is transferred to
In nucleus, and combined with specific DNA target mark, inducing DNA transcribes the expression with downstream albumen.
Fig. 2 is compound Cpd0460 and the experimental result of STAT3 Protein S H2 functional domain molecular dockings in embodiment 1, is changed
Compound Cpd0460 is presented in green box, and backbone carbon atoms (C) and latter end hydrogen atom (H) are unmarked, remaining all kinds of atom
With atomic symbol mark-oxygen (O), nitrogen (N) and sulphur (S);On Stat3 Protein Ss H2 interval, with Stat3-I-Q molecule phases
The key amino acid of interaction has:Lysine K591 and arginine R609 and tryptophan W632 use respectively K591, R609 and W632
Mark;The interval beta- of Stat3 Protein Ss H2 is folded, alpha spirals and random coil respectively with delaying straight band, hurricane band and thin
Pipe is represented.
Fig. 3 is the experimental data with polypeptide BIAcore of compound Cpd0460 in embodiment 2, (a) in different concentration
Under, BIAcore difference in signal strength [(Stat3-I-Q is combined with MALDI-PSD)-(Stat3-I-Q and non-phosphoric acid is measured for the first time
Change polypeptide combination)] time dependent indicatrix;B the mean value of () normalized measurement result twice is with change in concentration
Indicatrix, the italic numeral on right side represents the concentration of each indicatrix.
Fig. 4 is the test of the protein immunoblot (Western blot) of Cpd0460 in embodiment 3, upper glue-phosphorylation
Stat3 albumen is measurement theme, and the next glue-total amount Stat3 albumen is measurement percentage positive control;According to the test, compound
At concentration 5 (uM), Stat3 albumen is substantially reduced.
Fig. 5 is the test of phosphorylation Stat3 (Y705) protein immunoblot of the cellular level of Cpd0460 in embodiment 4.
Abscissa is Log (compound concentration) (concentration unit:Mole (M));Surveyed concentration is respectively:0.5,1,5,10,50,100 He
500 micro- rub (uM). ordinate for phosphorylation Stat3/ total amount Stat3 percentage. gained IC50 is 4.6 micro- to rub (uM).
Fig. 6 is the MTT cell apoptosis assays of compound Cpd0460 in embodiment 5
Fig. 7 is compound Cpd0460 organic synthesis route maps in embodiment 6
Specific embodiment
To describe technology contents of the invention, structural feature in detail, purpose and effect being realized, below in conjunction with embodiment
And coordinate accompanying drawing to be explained in detail.
Embodiment 1:Molecular docking (docking) is tested
Method:In order to the selective target for providing one group of rational computer forecast attacks the chemical probe of Stat3, we
It is main with phosphorylation TYR (pY-705) calmodulin binding domain CaM in Stat3 SH2 areas as computer coordination simulation (docking) site
To include phosphorylated tyrosine action site R609 and hydrophobic effect site W623.The structure coordinate of Stat3 SH2 is taken at albumen
Matter structural database (PDB data bank, ID:1BG1).Selected chemical molecular storehouse (Chemical compound
Library) it is LIFE CHEMICALS.The method of molecular docking (docking):All of computer coordination simulation
(docking) experiment is completed on the operating platform of Schrodinger-Maestro, computer coordination simulation used
(docking) instrument is Glide.First, by Stat3 SH2 from PDB data bank take out and under be loaded in Schrodinger
Operating platform-Maestro.After removing water, it is plus hydrogen atom and electric charge and by PDB file translations by the amino acid of Stat3 SH2
Maestro files.(mainly include phosphorylated tyrosine action site R609 and hydrophobic effect site according to selected site
W623) calculate, determine potential energy level (potential gradient) and make the experiment (3- of computer coordination simulation (docking)
5).Interpretation of result:Fraction (Score) and conformation and transactional analysis according to simulation (docking).We choose optimum
200 compounds make the experiment test in downstream.Cpd0460 conformations are shown in respectively Fig. 1.To verify the 200 of computer simulation prediction
Whether remaining compound can suppress the interaction of Stat3 and the polypeptide of fixed phosphorylation in molecular level, and we apply SPR skills
Art, on the instruments of BIAcore 3000, operates and completes this test.
Embodiment 2:BIAcore is tested
Method:Selected compounds are at 25 DEG C, by phosphoric acid with the experiment (BIAcore) of Stat3 intermolecular interactions
Change polypeptide to be fixed on the biochip of the BIAcore 3000 of streptavidin attachments (biosensor), flowing used
Buffer solution is the Tris buffer of the 20mM concentration of pH8 and contains water-soluble with the mercaptoethanol and 5%DMSO of 2mM concentration
Liquid, the speed of its flowing is 10uL/min.Before test, Stat3 albumen and the selected compounds of 500nM concentration are mixed into determined dense
Degree 0.1,0.5,1,5,10,50,100,500uM.Every time after test, rinsed with the glycine of the 100mM of the 10uL that pH is 1.5
Biochip (biosensor) is treating next test.The Stat3 albumen of the 500nM without medicine mixing is from initial to termination root point
Do not test once to determine whole test system normal operation (6) all the time.Experiment (BIAcore) interpretation of result:Cpd0460 is not
With the time dependent indicatrix of BIAcore signals visible (Fig. 3 (a)) of concentration, (abscissa numeral 0 in Fig. 3 (a), 50,
100th, different time points is represented respectively within 150,200,250,300,350,400 and 450 seconds.The experimental result of BIAcore is by table
The indicatrix of the mean value with change in concentration of normalized measured value twice is shown as, normalization BIAcore signals are not assimilate
The measured value of compound is multiplied by 100 (see Fig. 3 (b)) divided by the reference point without compound, abscissa numeral 0 in Fig. 3 (b), 0.1,
0.5th, 1,5,10,50 and 100uM compound concentration is represented respectively.(in indicatrix Fig. 3 (b), Diamond spot represents each concentration
The measured value of BIAcore signals, the vertical short wires on Diamond spot represent the standard error for measuring twice).Cpd0460 suppresses 50%
Stat3 and the concentration value (IC50) of compound of interaction of MALDI-PSD be all 1-5 (uM).Above-mentioned experimental evidence table
It is bright:Cpd0460 is combined and can be suppressed the Stat3 of half and the phase of MALDI-PSD under the low concentration of sub-micromolar with Stat3
Interaction.
Embodiment 3:Protein immunoblot (Westernblot)
Method:The experimental technique of protein immunoblot (Western blot):At the standard conditions, cultivate in six orifice plates
People's liver HCC (HepG2).Respectively with variable concentrations -0.5,1,5,10 (uM), with compound treated cells and to cultivate 1 little
When.Cell being processed with the IL-6 that concentration is 30ng/ml and cultivating half an hour go to stimulate Stat3 phosphorylations.After cell is collected, with height
Salt buffer (high-salt buffer) liquid separates albumen.Albumen after separation mixes with SDS, at 100 DEG C, heats 5 minutes.
Electrophoresis is done in SDS-PAGE polyacrylamide gels, the albumen of different quality is distinguished and fix, then by protein delivery to PVDF
Film simultaneously is gone to cover pvdf membrane with BSA.Molecular weight marker is inserted in advance SDS-PAGE glue and is transferred to pvdf membrane.Use anti-phosphorus
The first antibody of acidifying pY705-Stat3 and the first antibody of anti-total amount Stat3 go to detect phosphorylation pY705-Stat3 and total
Amount Stat3;With the chimeric sheep-anti-mouse IgG of HRP as enzyme target SA.Detectable signal is removed with chemical photosensitive system is strengthened.
Before the detection of total amount Stat3 antibody is transformed into, gone with buffer solution-Restore Western Blot Stripping Buffer
Detectable signal (7).The experimental result of protein immunoblot (Western blot):Upper glue is phosphorylation Stat3, and the next glue is
Total amount Stat3, signal shows from left to right:First is classified as the double negative controls of signal factor-compound (stimulates and while nothing without IL-6
Compound is added), second is classified as the n- compound negative control of signal factor (IL-6 stimulates and adds without compound simultaneously), and the 3rd
Arrange and be followed by, in the case where signal factor stimulates, the compound of variable concentrations (0.5,1,5,10 micromole) is to phosphorylation Stat3
Interference and result;Its result shows the ability that Cpd0460 has significant suppression Stat3 phosphorylations under sub- molar concentration.
Embodiment 4:Phosphorylation Stat3 (Y705) protein immunoblot (the Cell-based ELISA of cellular level
Phospho-STAT3(Y705)immunoassay)
The experimental technique of phosphorylation Stat3 (Y705) protein immunoblot of cellular level:By about the 20000 of 100 microlitres
Individual MBA-MD-231 population transplants are in each hole of 96 orifice plates (bottom hole is transparent and face is surveyed for black in hole).Cultivated
5% gas concentration lwevel, in the cell culture incubator (cell culture incubator) at a temperature of 37 DEG C overnight.Second
My god, with changing and thing processes cell (compound concentration is respectively 0.5,1,5,10,50,100,500 micromole (uM)) and by chemical combination
Cell after thing process places cell culture incubator culture one hour.Then, with cell factor-IL-6 cell is processed with hyperplasia
Stat3 phosphorylations are simultaneously placed cell culture incubator culture half an hour, and IL-6 concentration is 30ng/ml.With 4% good fortune of 100 microlitres (ul)
The fixed cell of your Malin (formaldehyde) is simultaneously cultivated 20 minutes at room temperature.After three times are rinsed, with the 0.6% of 100 microlitres
H2O2 process cell and in incubated at room temperature 20 minutes.After three times are rinsed, processed with stop buffer solution (Blocking buffer)
Cell is simultaneously cultivated 60 minutes at room temperature.Three times rinse after, with first antibody (Primary anti-body) mixed liquor (rabbit
The antibody of the Stat3 antibody of 705 tyrosine of anti-phosphorylation and the anti-pervasive Stat3 of mouse) process cell and place 2 DEG C of refrigerators
Overnight incubation.After three times are rinsed, with second antibody (Secondary anti-body) mixed liquor (sheep of HRP enzyme conjugations-anti-
The sheep of rabbit igg antibody and AP enzyme conjugations-anti-mouse IgG antibody) cell is processed, and cultivate two hours at room temperature.Lavation buffer solution
(Washing buffer) is rinsed twice and after 1X PBS rinse twice, is located with 75 microlitres of the first substrate (Substrate)-F1
Reason cell is simultaneously wrapped up with tin platinum paper, places room temperature 30 minutes.Cell is processed with 75 microlitres of the second substrate (Substrate)-F2
And wrapped up with tin platinum paper, place room temperature 30 minutes.Finally, solution device (fluorescence plate are read with fluorescence labeling
Reader, infinite-200, Tecan) read solution data.The IgG antibody of HRP enzyme conjugations excitation state wavelength -540nm, radiation
State wavelength -600nm is explaining;The IgG antibody of AP enzyme conjugations excitation state wavelength -360nm, radiant state wavelength -450nm are explaining
(8)。
The experimental result of phosphorylation Stat3 (Y705) protein immunoblot of cellular level:Cell based ELISA
The experimental result of immunoblot assay is shown in Fig. 5.Abscissa is the Log values of compound concentration, and compound concentration unit is to receive
Mole (nM);Surveyed compound concentration is respectively:0.5th, 1,5,10,50,100 and 500 are micro- rubs (uM).Ordinate is phosphorylation
(Stat3P705-STAT3) divided by percentage (the Ratio of pYSTAT3/Total of total amount Stat3 (Total STAT3)
STAT3).The test result of the Immunoblot-IC50 of gained Cpd0460 is respectively 4.6 (uM).Above the results show:
Under the concentration of sub-micromolar, Cpd0460 can effectively suppress a kind of MBA-MD-231 (breasts of Stat3 signals Non-intermittent activation
Gland cancer cancer cell) cell line Stat3 phosphorylations.
Embodiment 5:The experiment of induced breast cancer cancer cell-apoptosis MTT
Method:MTT is widely used in the detection of cell propagation and cytotoxicity.Our MTT experiment is mainly medicine
Detection to the cytotoxicity of in vitro culture.Preparatory work of experiment:Stimulating factor:IL-6;Compound:Cpd0460, test cell:
HepG2, MDA-MB-231 negative control cell:MCF-7, dry powder solvent:DMSO or sterilizing ddH20, medicine:WP1066、
F1566-0352、F1566-0424、F1566-0460.Experimental procedure:1st, first day by hepG2, MDA-MB-231, MCF-7 tri-
Kind 5000/hole of cell count bed board in good condition is in 96 orifice plates.2nd, IL-6 is overnight added to stimulate cell, IL-6 final concentrations afterwards
For 30ng/ml, stimulation time is 30min.Then several cells distinguish drug-treated, and dosing final concentration is with 1,3,10,30,100
(uM) several gradients carry out drug-treated, and continuously cultivate 48h.3rd, after drug-treated, MTT 10 microlitres of (reagents of reagent are added
Box), 37 degree are incubated 4 hours, are subsequently adding 100 microlitres of Formanzan solution to being completely dissolved (4 hours or so), upper ELIASA
Readings (570nm), records result.
Experimental result and analysis twice understands:The OD values that compound Cpd0460 is measured in MDA-MB-231 cells are big
In the OD values of MCF-7 cells, the effect for illustrating this compound inducing mammary JEG-3 (MDA-MB-231) apoptosis is better than the moon
Property control MCF-7 cells.
Embodiment 6:Organic synthesis
Method:The chloro- 1,4-naphthoquinones of 2- (0.5mmol) and 4- methoxybenzenesulphoismides (0.6mmol) are dissolved in into tetrahydrofuran
(1.8ml) in, stirring adds titanium tetrachloride tetrahydrofuran compound (0.6mmol) at 0 DEG C, and adds triethylamine (1.3mmol).
Mixture is stirred to room temperature in 80w heated under microwave conditions to 60 DEG C of reaction 1h.Reaction is cooled to room temperature and adds 20ml acetic acid
Ethyl ester.Material is filtered by diatomite in reaction bulb, and ethyl acetate washing, filtrate is spin-dried for.10ml dichloros are added in thing is spin-dried for
Ethane, is filtered by diatomite, is spin-dried for after filtrate that residue is dissolved in the tetrahydrofuran of 10ml.Add in tetrahydrofuran solution
3- sulfydryl -1 of 0.5mmol, 2,4- triazoles, stirring reaction 4h under room temperature condition, and thing is spin-dried for the dissolving of 10ml ethyl acetate.Plus
Enter 5ml water and 2.5mmol sodium thiosulfate.Mix 1h.Layering extraction, water is washed through three 10ml ethyl acetate
Afterwards, organic phase is used in mixed way into 25ml saturated common salt water washings, after anhydrous sodium sulfate drying, is filtered, be spin-dried for slightly being produced
Thing, carries out crude product pillar layer separation and obtains target product.
Citation
1.Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al.
(1999)Stat3 as an Oncogene.Cell 98:295-303.
2.Darnell JE(2005)Validating Stat3 in cancer therapy.Nature Medicine
11:595-596.
3.Becker S, Groner B, Muller CW (1998) Three-dimensional structure of the
Stat3[beta]homodimer bound to DNA.Nature 394:145-151.
4.Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, et al. (1998)
Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA.Cell
93:827-839.
5.Totrov M, Abagyan R (1997) Proteins 1:215-220.
6.Jason-Moller L, Murphy M and Bruno J (2006) Overview of Biacore
Systems.Current Protocols in Proteins Science, John Wiley & Sons Inc., 19.13.1-
19.13.14,
7.Towbin H, Staehelin T, Gordon J. (1979) Electrophoretic transfer of
proteins from polyacrylamide gels to nitrocellulose sheets:procedure and some
Application, Proc Natl Acad Sci USA 76 (9):4350-4354.
8.Cell-Based ELISA Human/Mouse Phospho-STAT3 (Y705) immunoassay, Catalog
No.KCB4607,2008 R&D Systems, Inc.726005.0
9.Schust J, Sperl B, Hollis A, Mayer TU and Berg T (2006) Stattic:A small-
molecule inhibitor of STAT3 Activation and Dimerization.Chemistry &
Biology13:1235-1242.
10.Sano S, Chan K, Carbajal S, Clifford J, Peavey M, Kiguchi K, Itami S,
Nickoloff B, and DiGiovanni (2005) Stat3 links activated keratinocytes and
immunocytes required for development of psoriasis in a novel transgenic mouse
Model.Nature Medicine 11,43-49.
Claims (3)
1. the signal transducting system inhibitor compound of following chemical formula is preparing the application for the treatment of cancer medicine:
。
2. the application according to claim 1, it is characterised in that the medicine is oral drugs or intravenous (IV) drug.
3. the application according to claim 1, it is characterised in that the medicine is the medicine for treating breast cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510757621.9A CN106668008A (en) | 2015-11-10 | 2015-11-10 | Target anti-cancer medicine based on STAT3 (Signal Transducers and Activators of Transcription type 3) protein target spot |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510757621.9A CN106668008A (en) | 2015-11-10 | 2015-11-10 | Target anti-cancer medicine based on STAT3 (Signal Transducers and Activators of Transcription type 3) protein target spot |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106668008A true CN106668008A (en) | 2017-05-17 |
Family
ID=58863424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510757621.9A Pending CN106668008A (en) | 2015-11-10 | 2015-11-10 | Target anti-cancer medicine based on STAT3 (Signal Transducers and Activators of Transcription type 3) protein target spot |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106668008A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108623582A (en) * | 2017-10-10 | 2018-10-09 | 河南省锐达医药科技有限公司 | A kind of novel preparation method containing substituent pyridine and pyrimidine compound |
CN110393718A (en) * | 2019-08-20 | 2019-11-01 | 青岛海洋生物医药研究院 | Uses and research methods of atopasa bromide as a novel inhibitor of JAK-STAT3 signaling pathway |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101836971A (en) * | 2010-05-21 | 2010-09-22 | 徐学军 | Application of compound in aspect of preparing drug for treating cancer or psoriasis |
CN104736202A (en) * | 2012-08-22 | 2015-06-24 | 康奈尔大学 | Methods for inhibiting fascin |
-
2015
- 2015-11-10 CN CN201510757621.9A patent/CN106668008A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101836971A (en) * | 2010-05-21 | 2010-09-22 | 徐学军 | Application of compound in aspect of preparing drug for treating cancer or psoriasis |
CN104736202A (en) * | 2012-08-22 | 2015-06-24 | 康奈尔大学 | Methods for inhibiting fascin |
Non-Patent Citations (2)
Title |
---|
HELEN HA等: "Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models", 《JOURNAL OF CHEMICAL INFORMATION AND MODELING》 * |
JIE QIN等: "Identification of a Novel Family of BRAFV600E Inhibitors", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108623582A (en) * | 2017-10-10 | 2018-10-09 | 河南省锐达医药科技有限公司 | A kind of novel preparation method containing substituent pyridine and pyrimidine compound |
CN110393718A (en) * | 2019-08-20 | 2019-11-01 | 青岛海洋生物医药研究院 | Uses and research methods of atopasa bromide as a novel inhibitor of JAK-STAT3 signaling pathway |
CN110393718B (en) * | 2019-08-20 | 2022-10-04 | 青岛海洋生物医药研究院 | Application and research method of atropa Sha Xiusuan as novel JAK-STAT3 signal pathway inhibitor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zisi et al. | Targeting ribosome biogenesis in cancer: lessons learned and way forward | |
Abdelhameed et al. | Binding of Janus kinase inhibitor tofacitinib with human serum albumin: multi-technique approach | |
CN101836971A (en) | Application of compound in aspect of preparing drug for treating cancer or psoriasis | |
Kumar et al. | Design and synthesis of non-covalent imidazo [1, 2-a] quinoxaline-based inhibitors of EGFR and their anti-cancer assessment | |
Boichuk et al. | The design, synthesis, and biological activities of pyrrole-based carboxamides: the novel tubulin inhibitors targeting the colchicine-binding site | |
Snegur | Modern trends in bio-organometallic ferrocene chemistry | |
Liu et al. | Organic‐Platinum Hybrids for Covalent Binding of G‐Quadruplexes: Structural Basis and Application to Cancer Immunotherapy | |
Masciocchi et al. | Biological and computational evaluation of an oxadiazole derivative (MD77) as a new lead for direct STAT3 inhibitors | |
Peyressatre et al. | Identification of quinazolinone analogs targeting CDK5 kinase activity and glioblastoma cell proliferation | |
da Silva et al. | Ruthenium (II) diphosphine complexes with mercapto ligands that inhibit topoisomerase IB and suppress tumor growth in vivo | |
Elrayess et al. | Discovery of potent dual EGFR/HER2 inhibitors based on thiophene scaffold targeting H1299 lung cancer cell line | |
Yadav et al. | Design, synthesis and anticancer activity of 2-arylimidazo [1, 2-a] pyridinyl-3-amines | |
Deiana et al. | A minimalistic coumarin turn-on probe for selective recognition of parallel G-quadruplex DNA structures | |
Wang et al. | The configuration of GRB2 in protein interaction and signal transduction | |
CN106668008A (en) | Target anti-cancer medicine based on STAT3 (Signal Transducers and Activators of Transcription type 3) protein target spot | |
Dan et al. | Crosstalk between EGFR and integrin affects invasion and proliferation of gastric cancer cell line, SGC7901 | |
Oberhuber et al. | Synthesis and anticancer evaluation of new indole-based tyrphostin derivatives and their (p-cymene) dichloridoruthenium (II) complexes | |
Khan et al. | Design, synthesis, and biological evaluation of novel dihydropyridine and pyridine analogs as potent human tissue nonspecific alkaline phosphatase inhibitors with anticancer activity: ROS and DNA damage-induced apoptosis | |
de Souza Gama et al. | Novel Dihydropteridinone Derivatives As Potent Inhibitors of the Understudied Human Kinases Vaccinia-Related Kinase 1 and Casein Kinase 1δ/ε | |
Moghoufei et al. | Synthesis of 4-hydroxy-L-proline derivatives as new non-classical inhibitors of human carbonic anhydrase II activity: An in vitro study | |
Zhang et al. | Identification of imidazo [4, 5-c] pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma | |
Zhao et al. | Synthesis, anticancer activity and mechanism of action of Fe (III) complexes | |
Li et al. | Design, synthesis, and anticancer activity of three novel palbociclib derivatives | |
Wang et al. | Ruthenium (II) Complexes Coupled by Erianin via a Flexible Carbon Chain as a Potential Stabilizer of c-myc G-Quadruplex DNA | |
Liu et al. | Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170517 |
|
WD01 | Invention patent application deemed withdrawn after publication |